The CEO's total reported compensation of $4,178,008 is within a defensible range for a biotech CEO at Omeros's current market cap of approximately $725 million, and the prior year say-on-pay vote received strong 89% support, well above the 70% threshold that would require action. On pay-for-performance alignment, Omeros's 3-year stock return of +90.1% materially outpaces the XBI (SPDR S&P Biotech ETF) benchmark return of +84.6%, meaning shareholders have been rewarded alongside executive pay; while the equity program relies solely on time-vesting stock options without explicit performance conditions, the stock option structure does create alignment in that executives only profit if the share price rises above the grant price. The company has a meaningful clawback policy effective October 2023, and although the CEO's annual bonus is set at 100% of base salary (a generous target), the underlying 2024 performance objectives — including the FDA approval of YARTEMLEA and the $240M Novo Nordisk transaction — represent genuinely significant clinical and business milestones that justify the payout.

Ernst & Young LLP is a Big 4 firm fully appropriate for Omeros's size and complexity, satisfying the auditor adequacy requirement for a company with a market cap around $725 million. The proxy filing excerpt provided does not include the auditor fee table, so the non-audit fee ratio cannot be calculated — under policy, the tenure trigger requires confirmed data and cannot fire without it, and the fee ratio trigger likewise cannot fire without fee data; absent any confirmed trigger, the default FOR vote applies. No material financial restatements attributable to audit failure are disclosed in the filing.